Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancerKosaku Mimura, Takashi Ogata, Phuong H D Nguyen, Souvick Roy, Hassen Kared, Yate-Ching Yuan, Michael Fehlings, Yuya Yoshimoto, Daisaku Yoshida, Shotaro Nakajima, Hisashi Sato, Nozomu Machida, Takanobu Yamada, Yohei Watanabe, Tomoaki TamakiSee the full list of authors
30 January 2024
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancerPénélope Desroys du Roure, Laurie Lajoie, Aude Mallavialle, Lindsay B Alcaraz, Hanane Mansouri, Lise Fenou, Véronique Garambois, Lucie Rubio, Timothée David, Loïs Coenon, Florence Boissière-Michot, Marie-Christine Chateau, Giang Ngo, Marta Jarlier, Martin VillalbaSee the full list of authors
30 January 2024
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term respondersBrandon M Huffman, Harshabad Singh, Lestat R Ali, Nora Horick, S Jennifer Wang, Megan T Hoffman, Katherine A Metayer, Shayla Murray, Alexandra Bird, Thomas A Abrams, Leah H Biller, Jennifer A Chan, Jeffrey A Meyerhardt, Nadine J McCleary, Wolfram GoesslingSee the full list of authors
25 January 2024
Cryoablation triggers type I interferon-dependent antitumor immunity and potentiates immunotherapy efficacy in lung cancerChuanjia Gu, Xue Wang, Kaiyu Wang, Fangfang Xie, Luonan Chen, Hongbin Ji, Jiayuan Sun
25 January 2024
Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancersJianfei Qian, Qiang Wang, Liuling Xiao, Wei Xiong, Miao Xian, Pan Su, Maojie Yang, Chuanchao Zhang, Yabo Li, Ling Zhong, Siddhartha Ganguly, Youli Zu, Qing Yi
24 January 2024
NKG2ACD8 T cells infiltration determines immunosuppressive contexture and inferior response to immunotherapy in clear cell renal cell carcinomaYouqi Qiu, Li Liu, Wenbin Jiang, Ziyang Xu, Jiahao Wang, Siyuan Dai, Jianming Guo, Jiejie Xu
23 January 2024
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146Vicky Makker, Matthew H Taylor, Carol Aghajanian, Allen L Cohn, Marcia S Brose, Christopher Di Simone, Zhu Alexander Cao, Leah Suttner, Andrey Loboda, Razvan Cristescu, Petar Jelinic, Robert Orlowski, Lea Dutta, Junji Matsui, Corina E DutcusSee the full list of authors
19 January 2024
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trialNikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur, Bjørnar Gilje, Beate Boge, Andrea Gombos, Ragnhild Sørum Falk, Randi R. Mathiesen, Lars Julsrud, Øystein Garred, Hege G. Russnes, Ragnhild Reehorst Lereim, Sudhir Kumar Chauhan, Ole Christian Lingjærde, Claire DunnSee the full list of authors
19 January 2024
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic reviewPeter Galle, Richard S Finn, Catherine Ruth Mitchell, Kerigo Ndirangu, Zahra Ramji, Gabrielle Sophie Redhead, David J Pinato
18 January 2024
Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1/PD-L1 inhibitorsXiang Li, Yangzhong Zhou, Bing Xu, Yunhe Qin, Jiuliang Zhao, Mengtao Li, Jiachen Xu, Guanqiao Li
17 January 2024
